Related Experiment Video

Updated: May 24, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Novel patented SRC kinase inhibitor

Xiao-Ling Lu1, Xiao-Yu Liu, Xin Cao

  • 1State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, No. 345, Fenglin Rd., Shanghai 200032, People's Republic of China.

Current Medicinal Chemistry
|March 15, 2012
PubMed

Insights

Src family kinases (SFKs) are crucial for cell signaling but their hyper-activation drives cancer. This review covers recent patents on Src kinase inhibitors developed as targeted cancer therapies.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Pharmacology

Background:

  • Src family kinases (SFKs) regulate critical cellular signal transduction pathways.
  • Dysregulated SFK activity is implicated in uncontrolled cell proliferation and the development of various cancers.
  • Targeting SFKs offers a promising strategy for cancer therapy by inhibiting aberrant signaling.

Purpose of the Study:

  • To review predominant patents concerning Src kinase inhibitors.
  • To highlight recent advancements in the design and development of these inhibitors as anticancer agents.

Main Methods:

  • Literature search and analysis of recent patent filings related to Src kinase inhibitors.
  • Evaluation of inhibitor design, synthesis, and reported anticancer activity.

Main Results:

  • Significant progress has been made in developing Src kinase inhibitors.
  • Numerous patents demonstrate the ongoing efforts in creating novel Src-targeted compounds.
  • Inhibitors are designed to block key signaling pathways driving cancer cell proliferation.

Conclusions:

  • Src kinase inhibitors represent a vital area of research and development in oncology.
  • Patented Src inhibitors show potential as targeted therapies for various cancers.
  • Continued innovation in this field is expected to yield new therapeutic options.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...